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Abstract: Combining the concept of magnetic drug targeting and photodynamic therapy is a 
promising approach for the treatment of cancer. A high selectivity as well as significant fewer 
side effects can be achieved by this method, since the therapeutic treatment only takes place 
in the area where accumulation of the particles by an external electromagnet and radiation 
by a laser system overlap. In this article, a novel hypericin-bearing drug delivery system has 
been developed by synthesis of superparamagnetic iron oxide nanoparticles (SPIONs) with a 
hypericin-linked functionalized dextran coating. For that, sterically stabilized dextran-coated 
SPIONs were produced by coprecipitation and crosslinking with epichlorohydrin to enhance 
stability. Carboxymethylation of the dextran shell provided a functionalized platform for linking 
hypericin via glutaraldehyde. Particle sizes obtained by dynamic light scattering were in a range 
of 55–85 nm, whereas investigation of single magnetite or maghemite particle diameter was 
performed by transmission electron microscopy and X-ray diffraction and resulted in approxi-
mately 4.5–5.0 nm. Surface chemistry of those particles was evaluated by Fourier transform 
infrared spectroscopy and ζ potential measurements, indicating successful functionalization and 
dispersal stabilization due to a mixture of steric and electrostatic repulsion. Flow cytometry 
revealed no toxicity of pure nanoparticles as well as hypericin without exposure to light on 
Jurkat T-cells, whereas the combination of hypericin, alone or loaded on particles, with light-
induced cell death in a concentration and exposure time-dependent manner due to the generation 
of reactive oxygen species. In conclusion, the combination of SPIONs’ targeting abilities with 
hypericin’s phototoxic properties represents a promising approach for merging magnetic drug 
targeting with photodynamic therapy for the treatment of cancer.
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Introduction
One of the most promising approaches for cancer treatment in the last few years is 
magnetic drug targeting (MDT).1–3 In this concept, drug accumulation in the tumor can 
be achieved with a drug-loaded magnetic carrier system, which is physically directed 
to the region of interest by an external magnetic field.4,5 In comparison to conventional 
drug administration, this leads to an effective increase in the drug concentration in 
the affected tissue as well as a reduced drug concentration in the rest of the body.6,7 
Thus, a decrease in systemic side effects, such as nausea, hair loss, or neurotoxicity, 
can be achieved.8–10
An interesting feature of MDT is that it can be combined with other cancer 
treatment strategies such as photodynamic therapy (PDT), to create an even more 
selective treatment. Magnetic particles that are commonly used for MDT are super-
paramagnetic iron oxide nanoparticles (SPIONs), including magnetite (Fe
3
O
4
), 
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maghemite (γ-Fe
2
O
3
), or other ferrites.11–13 They are bio-
compatible and have superparamagnetic characteristics 
depending on their size, which leads to an extensive use 
of these particles in bioseparation, hyperthermia, magnetic 
resonance imaging, and drug targeting.6,14–19 SPIONs have 
a large surface-area-to-volume ratio, which is the reason 
why they tend to agglomerate in order to reduce their sur-
face energy.20 To prevent the particles from this behavior, 
we used dextran as a stabilizing agent. It is a biocom-
patible, biodegradable, and water-dispersible branched 
polysaccharide.21,22 Additionally, the hydroxyl groups of 
this polymer can be used to add various functionalities, 
which can then be further used to link the photosensitizer 
(PS), in our case, hypericin.23
Hypericin, a naturally occurring PS, is an essential 
component of the plant Hypericum perforatum, also known 
as St John’s wort. Besides its natural extraction, hypericin 
can also be synthesized as described by Karioti and Bilia.24 
As a derivative of the anthraquinone, hypericin consists of 
aromatic rings that form a planar molecule. Its delocalized 
π-electron system is responsible for the photoactive behavior, 
which is used in PDT (Figure 1). There, upon activation by 
light, PS transfers its energy to other molecules finally gen-
erating highly reactive oxygen species (ROS). In the vicinity 
of cell components, these intermediates cause biological 
damage by oxidation.25 Usually, the PS such as hypericin is 
applied systemically, which leads to a high systemic pho-
tosensitivity accompanied by a high rate of discomfort to 
the patients. Hence, the combination of MDT with PDT can 
reduce this disadvantage and result in a high selectivity as 
well as significant fewer side effects, since the therapeutic 
treatment only takes place in the area where the accumulation 
of the particles due to the external magnet and the radiation 
by a laser system overlap.
In this work, we describe a novel approach, where such a 
drug delivery vehicle is designed based on the combination 
of MDT and PDT.
Materials and methods
Materials
Chemicals for the iron oxide nanoparticles synthesis, acetic 
acid (water free), acetonitrile (HPLC gradient grade), ethanol 
(HPLC gradient grade), methanol (MeOH, HPLC gradient 
grade), MUSE count and viability assay kit, sodium dihy-
drogen phosphate, as well as sterile and unsterile Rotilabo®-
syringe filters with cellulose mixed ester membrane have 
been provided by Carl Roth (Karlsruhe, Germany) and Merck 
(Darmstadt, Germany), respectively.
Dextran from Leuconostoc spp. (molecular weight = 
6 kDa), epichlorohydrin (ECH), ammonium acetate, 
chloroacetic acid, 2′,7′-dichlorofluorescein diacetate 
(DCFH-DA), ethyl chloroformate, as well as phosphate 
buffered saline (PBS) were purchased from Sigma-Aldrich 
(Hamburg, Germany). Sulfosalicylic acid solution (20%) 
was obtained from AppliChem (Darmstadt, Germany). 
RPMI 1640 medium, F-12K medium, l-glutamine, Hoechst 
33342 (Hoe), Annexin A5-Fitc (AxV), and hexamethylin-
dodicarbocyanine iodide dye (DiI) were purchased from 
Thermo Fisher Scientific (Waltham, MA, USA). Hypericin 
was purchased from Alfa Aesar (Karlsruhe, Germany), and 
fetal calf serum (FCS) and l-glutamine from Biochrom 
(Berlin, Germany). Ringer’s solution containing 0.9% NaCl 
(w/v) was supplied by DeltaSelect (Rimbach, Germany). 
SPECTRA/POR® 6 dialysis tubing with a molecular weight 
cut-off (MWCO) of 10 kDa and a diameter of 29 mm 
was purchased from Serva Electrophoresis (Heidelberg, 
Germany). Vivaspin 20 ultrafiltration units with 100 kDa 
MWCO were supplied by Sartorius Stedim Biotech 
/LJKW 3KRWRVHQVLWL]HULQJURXQGVWDWH
3KRWRVHQVLWL]HULQH[FLWHGVWDWH
2[\JHQLQWLVVXH
5HDFWLYHR[\JHQVSHFLHV526
&HOOWR[LFLW\
Figure 1 schematic representation of principle of photodynamic therapy: a photosensitizer is excited by an external light stimulus.
Note: This energy can be transferred to oxygen in tissue, which leads to the formation of reactive oxygen species, causing oxidation of cellular components (eg, proteins, 
lipids, and DNA) and finally cell death.
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(Goettingen, Germany). Water used in all experiments was 
of bidistilled quality.
Preparation of functionalized dextran-coated 
sPIONs
Dextran-coated SPIONs (SPIONDEX) were synthesized in 
a cold gelation process, as described previously.26 In brief, 
an aqueous solution containing 8.8% (w/w) dextran, 2.4% 
(w/w) FeCl
3
⋅6H
2
O, and 0.9% (w/w) FeCl
2
⋅4H
2
O was prepared 
and filtered through a 0.22-µm membrane into an ice-cooled 
three-neck round-bottomed flask. Under an argon atmo-
sphere, the temperature was adjusted to 0°C–4°C. NH
3
 was 
added to the solution, which resulted in a green-brownish 
suspension. After heating the solution at 75°C, the formed 
particles were cooled and dialyzed against water (MWCO 
10 kDa) to remove excess salts. Redundant dextran was 
removed afterward by ultrafiltration in a centrifuge 5430R 
(Eppendorf, Hamburg, Germany) with Vivaspin20 filter units 
at 6,300× g for 10 minutes for multiple runs. The dextran 
molecules of the SPION coating were crosslinked with ECH. 
In this reaction, the pH of the particles was adjusted to basic 
conditions with 5 M NaOH and then ECH was added to a 
final concentration of 15% (v/v). The suspension was stirred 
for 24 hours and then it was again dialyzed against water 
for 24 hours, followed by ultrafiltration and sterile filtration 
through 0.22 µm filters.
The dextran coating of the particles was functionalized 
with carboxylic acid groups according to Huynh et al.23 
Briefly, the pH of the suspension was adjusted to 12–13 with 
5 M NaOH. After cooling the suspension, monochloroacetic 
acid was added and then it was heated to 60°C for 90 minutes, 
followed by neutralization with acetic acid. In the end, the 
particles were purified by dialysis against water and ultrafiltra-
tion. In the following, they are referred to as SPIONCMD.
The determination of the particles’ iron content was per-
formed photometrically as described by Dokuzovic.27
linking of hypericin to functionalized sPIONs
Hypericin was covalently bound to SPIONCMD via glutaral-
dehyde (GA). First of all, a 1% GA solution was prepared by 
diluting a commercial 25% GA stock solution with 10 mM 
phosphate buffer solution, and the particulate suspension 
was buffered with 10 mM NaH
2
PO
4
. Buffered suspension 
(5 mL) was mixed with 838 µL 1% GA and stirred for 
1 hour. Thereafter, an equal volume of hypericin (50 µg/mL 
in MeOH) was added and stirring was continued for further 
23 hours. The resulting samples were dialyzed against water 
to remove excess GA.
For the removal of unbound hypericin from the samples, 
a method was developed, based on different solubility-
behaviors of hypericin and SPIONCMD in alcoholic medium. 
While hypericin shows very good solubility in MeOH, 
SPIONCMD precipitates if MeOH content in the suspension is 
too high. Therefore, samples were diluted with MeOH until 
precipitation occurred and sedimentation was accelerated in 
a 5430R centrifuge at 7,200× g. As a result, SPIONCMD-Hyp 
deposited on the bottom and excess hypericin could be 
removed by decantation. The samples were refilled with 
MeOH to their original volume and dispersed by ultrasoni-
fication (ultrasonic finger Sonopuls, Bandelin, Germany) for 
30 seconds, before they were centrifuged again at 7,200× g 
for 10 minutes. This step is repeated five times, until the 
supernatant becomes clear. Finally, the samples were resus-
pended in water by ultrasonification (75 W for 30 seconds), 
which resulted in a stable colloid, and is referred to as 
SPIONCMD-Hyp.
Particle size and ζ potential measurement
The hydrodynamic size of the nanoparticles was acquired 
by dynamic laser scattering with a Nanophox (Sympatec, 
Clausthal-Zellerfeld, Germany) operated in cross-correlation 
mode. For the ζ potential measurements (Nanosizer ZS, 
Malvern Instruments, Herrenberg, Germany), which were 
performed at pH 7 and 25°C with a scattering angle of 90°, 
particles were dispersed in aqueous solutions. The experiments 
were performed in triplicates and, the results were averaged.
Fourier transform infrared spectroscopy
The chemical composition of lyophilized nanoparticle 
specimens was determined with the ALPHA FT-IR spec-
trometer (Bruker Corporation, Billerica, MA, USA). The 
spectra were collected in attenuated total reflection mode in 
the mid-infrared region from 4,000 to 400 cm−1, with a step 
size of 0.5 cm−1.
Determination of hypericin content
Prior to the determination of the hypericin content in drug-
loaded samples, nanoparticles had to be dissolved in acidic 
conditions at 99°C. Then, quantification of hypericin was 
done by high-performance liquid chromatography (HPLC), 
combined with an electrospray-ionization mass spectrometer. 
As a stationary phase, an XBridge Shield RP18 column 
(Waters, Milford, MA, USA) with a particle size of 3.5 µm, 
an interior diameter of 3.0 mm, and a length of 100 mm was 
used at a temperature of 30°C. The mobile phase consisted 
of acetonitrile, MeOH, and 20 mM ammonium acetate in 
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a volume ratio of 54:36:10 and was used with a flow rate 
of 1.0 mL/minute. The HPLC device was a Waters e2695 
series and the mass spectrometer was a Waters Acquity SQ 
detector (both Milford, MA, USA), with a desolvation tem-
perature of 450°C and detecting a mass-to-charge ratio of 
503 in ESI(−)-mode. Based on the reference samples, a linear 
calibration curve can be achieved, showing the dependence 
of hypericin concentration as a function of peak area and 
thus can be used to calculate the hypericin content of the 
particulate specimens. All measurements were performed 
in triplicates and the results were averaged.
Transmission electron microscopy
Transmission electron microscopy (TEM) images were taken 
by a CM300 UltraTWIN transmission electron microscope 
(Philips, Eindhoven, the Netherlands) operating at 300 kV 
in imaging mode. Samples were prepared by drop cast of 
a 10 µL aliquot of a diluted nanoparticle solution, on an 
Athene® grid (Plano GmbH, Wetzlar, Germany). The size 
distribution is determined by examination of an overview 
TEM image with the software ImageJ (version 1.48; National 
Institutes of Health, Bethesda, MD, USA).
X-ray diffraction
In this study, a Siemens D500 (Bruker AXS Inc., Madison, 
WI, USA) X-ray diffraction (XRD) device is used to per-
form a θ/2θ-measurement in order to determine the inter-
planar distances d
hkl
 and therefore the crystallinity of the 
samples. Lyophilized particles were mounted onto a sample 
holder. The Cu Kα beam with the wavelength λ=0.15418 
nm was used as an X-ray source and the angular range 
was 25°–70° with a step size of 0.02°/second and a dwell 
time of 1 second. Afterwards, the interplanar spacing was 
determined by Bragg’s law (1) and the lattice parameter a 
by Equation 2:
 d
hkl
= λ
θ2sin
 (1)
 d
a
h k lhkl
=
+ +2 2 2
 (2)
with θ as the diffraction angle and h, k, and l as the Miller 
indices of the diffraction plane.
According to the Debye–Scherrer formula, the crystallite 
size d
XRD
 for the sample is given by:
 d
XRD
= 0 9.
cos
λ
β θ
 (3)
where β is the full-width at a half maximum value of XRD 
diffraction peaks.
In vitro toxicity
cell line and culture condition
The in vitro toxicity of free and particle-bound hypericin was 
investigated in the nonadherent human T-cell leukemia cell 
line Jurkat (ACC 282, DSMZ, Braunschweig, Germany), 
cultured in RPMI 1640 medium supplemented with 10% FCS 
and 1% glutamine. Cells were cultured in a CO
2
 incubator 
(INCOmed, MEMMERT, Schwabach, Germany) at 37°C, 
95% humidified air and 5% CO
2
.
Analysis of Jurkat cells using flow cytometry
Before beginning every experiment, cell viability and cell 
count were determined using a Muse® Cell Analyzer (EMD 
Millipore, Billerica, MA, USA). Cells were adjusted to a 
concentration of 2×105 cells/mL in culture medium, and 
950 µL of the suspension were seeded in each well of a TC 
48-well plate (Sarstedt, Nümbrecht, Germany). Then, the 
wells were supplemented with 50 µL of the sterile-filtered 
samples. After preincubation of cells with free hypericin, 
particle-bound hypericin or free hypericin in the presence 
of particles for 2 hours, the cells were incubated for 2 hours, 
while in the dark (plates were wrapped with aluminum foil) 
the cells were excited with a slimlite LED white light source 
(40 W/m2, Kaiser, Buchen, Germany) for different time 
intervals (0, 5, 10, and 15 minutes) to start the phototoxic 
reaction of hypericin, followed by incubation for 16, 24, 
and 48 hours. Subsequently, cells were mixed and 50 µL of 
the cell suspension were taken out and incubated with 250 
µL freshly prepared staining solution, consisting of 1 µL/
mL Hoe, 0.5 µL/mL AxV, and 0.4 µL/mL DiI in Ringer’s 
solution for 20 minutes at 4°C.
Flow cytometry was performed with a Gallios cytofluo-
rometer (Beckman Coulter, Brea, CA, USA). Excitation for 
AxV-Fitc was at 488 nm, the Fitc fluorescence was recorded 
on an FL1 sensor (525/38 nm BP), the DiI fluorescence was 
excited at 638 nm and recorded on an FL6 sensor (675/ 
20 nm BP), and the Hoechst 33342 fluorescence was excited 
at 405 nm and recorded on an FL9 sensor (430/40 nm BP). 
Electronic compensation was used to eliminate bleed through 
fluorescence. Data analysis was performed with Kaluza 
software version 2.0 (Beckman Coulter).
Hoe has been used to differentiate between cells (Hoe 
positive) and particles (Hoe negative). DiI was added to 
measure mitochondrial membrane potential in viable (DiI 
positive) as well as apoptotic and necrotic cells (both DiI 
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negative). AxV serves as additional cell viability marker 
(AxV negative: viable; AxV positive: apoptotic/necrotic). 
During preparation steps, excitation by any ambient light 
was reduced to a minimum. All experiments were performed 
in triplicates and the results were averaged. The statisti-
cal significance of comparisons with the untreated control 
was investigated using Student’s t-test in Excel (Microsoft 
Corporation, Redmond, WA, USA) (*P,0.05, **P,0.005, 
and ***P,0.0005).
In vitro rOs determination
The amount of hypericin-produced ROS was determined 
using the fluorescence dye DCFH-DA. DCFH-DA was 
then incubated with the cells (2×105 cells/mL) in a con-
centration of 20 µM for 30 minutes in the dark at 37°C to 
ensure cell penetration. After that, cells were washed once 
and taken up in PBS. Suspensions (950 µL) were pipetted 
into each well of a 48-well plate and 50 µL of free hypericin, 
particle-bound hypericin, as well as a free hypericin in the 
presence of SPIONCMD were added to a drug concentration 
of 0.2 µg/mL and incubated for further 2 hours. Afterward, 
cells were excited with the LED white light source for 
60 seconds. After further incubation for 5, 45, and 85 minutes, 
300 µL of each well were taken out and analyzed in flow 
cytometry. DCFH was excited at 488 nm and its fluorescence 
was recorded on an FL1 sensor (525/38 nm BP). The corre-
sponding cell viability was determined by morphological cell 
analysis in a flow cytometer: the forward scatter, which is a 
measure for the size of the cell and can be used to determine 
between cell and nanoparticles, is plotted against the side 
scatter, which stands for the granularity of the cells. Experi-
ments were performed in quadruplicates and the results were 
averaged. The statistical significance of comparisons with 
the untreated control was investigated using Student’s t-test 
in Excel (Microsoft Corporation) (*P,0.05, **P,0.005, 
and ***P,0.0005).
Results and discussion
structural characterization of sPIONcMD-hyp
We first investigated the change in size and ζ potential 
after each preparation step of the particles, which is sum-
marized in Table 1. SPIONDEX, which is the building block 
of our system, has a hydrodynamic size of approximately 
56.3±1.2 nm and a relatively uncharged surface with a 
ζ potential of −5.3±0.3 mV. After the functionalization 
process, the hydrodynamic size is increased to 66.4±2.2 nm. 
Due to the anionic character of carboxyl groups, which 
are introduced to the particle surface, the ζ potential is 
decreased to −35.9±1.1 mV. The linkage between hypericin 
and SPIONCMD was achieved via GA, which changed the ζ 
potential to −40.7±0.2 mV and increased the hydrodynamic 
size to 84.5±0.3 nm. The obtained particles did not show any 
sign of precipitation after 12 weeks of storage.
Besides the change in ζ potential, the success of car-
boxymethylation of the dextran coating on the particles is 
also demonstrated in the fourier transform infrared spectra 
(Figure 2A). Both SPIONDEX and SPIONCMD exhibit a strong 
peak at 600 cm−1 that can be attributed to Fe–O surface 
vibrations.28 The presence of dextran can be ascertained by 
characteristic α-glucopyranose ring deformation modes at 
frequencies of 765, 845, and 914 cm−1. Absorption bands 
at 1,000–1,150 cm−1 correspond to C–O–C vibrations and 
peaks at 1,040–1,150 cm−1 to C=O vibrational modes.29 
In addition, C–H peaks of dextran were produced in a range 
of 1,250–1,460 cm−1 and further at around the frequency of 
2,900 cm−1.30 Absorption bands at 1,640 and 3,400 cm−1 are 
visible due to O–H deformation and stretching modes of 
hydroxyl groups, related to the dextran coating and physical 
adsorbed water.30 After functionalization, the particles show 
new bands at 1,720 cm−1 and 1,640 cm−1, which correspond 
to C=O stretches of carboxylic acid, and prove the success of 
the particle functionalization. After binding hypericin to the 
particles via GA, the peak ratios in the range between 1,800 
and 1,200 cm−1 change (Figure 2B). The main differences 
in the spectra are the reduction of the peak at 1,600 cm−1 
and the increase in the peak at 1,720 cm−1, which can also 
be attributed to C=O stretches by hypericin. However, GA 
molecules, which are not involved in the hypericin binding, 
might also contribute to the band changes.
In order to quantify the amount of hypericin, which 
is coupled to the particles, an HPLC-MS quantification 
method was developed. An exemplary chromatogram of 
hypericin with the aforementioned conditions is depicted 
in Figure 3A. The peak has a retention time of 2.4 minutes 
and a slight tailing. Figure 3B shows that there is a distinct 
linear correlation between the area under the curve and the 
Table 1 Particle sizes (volume mean diameter) and ζ potential 
in water at ph 7
Particle Hydrodynamic diameter 
by volume [nm]
ζ potential 
[mV]
sPIONDeX 56.3±1.2 −5.3±0.5
sPIONcMD 66.4±2.2 −35.9±1.1
sPIONcMD-hyp 84.5±0.3 −40.7±1.5
Abbreviations: sPIONDeX, dextran-coated sPIONs; sPIONcMD, functionalized 
dextran-coated sPIONs; sPION, superparamagnetic iron oxide nanoparticle; 
sPIONcMD-hyp, hypericin linked to sPIONcMD.
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Figure 2 FT-Ir spectra demonstrate the success of the functionalization of sPIONcMD.
Notes: The inset shows the introduction of peaks at 1,720 and 1,600 cm−1, which can be contributed to carboxyl groups (A). The spectra for sPIONcMD-hyp shows changes in 
relative peak intensities, which can be attributed to the linkage of hypericin and glutaraldehyde; the inset shows magnification of the important wavenumber range (B).
Abbreviations: FT-Ir, fourier transform infrared; sPIONcMD, functionalized dextran-coated sPIONs; sPION, superparamagnetic iron oxide nanoparticle; sPIONcMD-hyp, 
hypericin linked to sPIONcMD; sPIONDeX, dextran-coated sPIONs; au, arbitrary unit.
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Figure 3 exemplary hPlc esI-Ms chromatogram of hypericin (A). linear calibration curve (R2=0.9993) for the determination of the particles’ hypericin concentration (B).
Abbreviations: hPlc esI-Ms, high-performance liquid chromatography combined with an electrospray-ionization mass spectrometer; m, minutes.
hypericin concentration in the concentration range between 
25 and 2,000 ng/mL with an R2=0.9993. With this assay, the 
hypericin concentration of SPIONCMD-Hyp was determined 
as 6.9±0.8 µg/mL and in relation to the iron concentration 
it is 6.7±0.5 µg hypericin/mg iron, which is high enough 
for further biological tests.31,32 Washing of the particles 
12 weeks after fabrication and remeasuring the hypericin 
concentration resulted in similar contents, proving that 
the particles do not show drug leakage over the examined 
time period.
Overview TEM images of SPIONCMD and SPIONCMD-Hyp 
are depicted in Figure 4. Both samples show agglomeration 
of round iron oxide nanoparticles. The sizes of the clusters 
are consistent with dynamic light scattering experiments. 
Figure 5 displays the size distribution of the individual 
iron oxide cores which are the building blocks for the 
agglomerates. The distribution was derived from measur-
ing 200 particles within TEM pictures (data not shown) 
with the software ImageJ. The sizes for SPIONCMD ranged 
from 3.0 to 9.0 nm and had a mean value of 4.5±1.0 nm. 
SPIONCMD-Hyp has a similar distribution in the range between 
3.0 and 10.0 nm, with a mean value of 4.6±1.0 nm. It can be 
concluded that the core size distributions for both samples 
were quite narrow and in the same order of magnitude. 
These values are in good agreement for dextran-coated 
SPIONs in the literature.26,33,34
Examination of the crystalline structure and the crystal-
lite size were performed by recording an XRD pattern of 
SPIONCMD-Hyp, which is depicted in Figure 6. Occurring peaks 
are characteristic for the face-centered cubic spinel structure 
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of magnetite as well as maghemite, which only differ slightly. 
Thus, differentiation, whether magnetite, maghemite, or a 
combination of both has been formed, is not determinable 
only due to the XRD pattern. The major peak at 35.6° refers to 
the (311) plane, while less marked peaks at 30.3° (220), 43.4° 
(400) 57.3° (511), and 62.7° (440) indicate a small crystallite 
size.35,36 Taking Bragg’s law (Equation 1) into account, the 
interplanar spacing d
hkl
, corresponding to the (311) plane, 
can be calculated with its peak position to d
hkl
=0.25240 nm. 
By applying this result in Equation 2, the lattice parameter 
a can be determined to a=0.83713 nm. In comparison 
with literature values for magnetite (a=0.83967 nm) and 
maghemite (a=0.83457 nm), the lattice parameter is located 
right between both iron oxide forms.37 Based on this result, 
a definite determination, whether magnetite or maghemite is 
formed, cannot be done. However, it can be assumed that a 
mixture of both is present in the sample. It is thinkable that 
magnetite has been formed during precipitation under inert 
gas, but even storage at 4°C of the particles enables oxida-
tion and hence partial formation of maghemite.38 Moreover, 
the crystallite size can be estimated with the full width at a 
half maximum of the (311) peak by applying Equation 3. 
This results in d
XRD
≈5 nm for the SPIONCMD-Hyp sample and 
is in line with the mean value of the size distribution, which 
was acquired from TEM images.
Biological characterization of sPIONcMD-hyp
The toxicological impact of SPIONCMD, SPIONCMD-Hyp, and 
hypericin alone on Jurkat cells was determined using two 
fluorescent viability markers in flow cytometry. Healthy 
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cells exhibit a proton gradient of the inner mitochondrial 
plasma membrane, which generates the conversion from 
adenosine diphosphate to adenosine triphosphate. Therefore, 
DiI – a compound that penetrates the cytosol of the cells and 
accumulates in the active and vital mitochondria – was used 
to determine this membrane potential. A decrease in this 
potential is an indicator for apoptosis and necrosis.39 On the 
other hand, AxV serves as an alternative marker for dying and 
dead cells. AxV binds phosphatidylserine, which is acces-
sible in apoptotic cells due to exposition on the outer layer 
of the plasma membrane and in necrotic cells due to rupture 
of the plasma membrane. Viable cells, in contrast, have 
an  asymmetric plasma membrane with phosphatidylserine 
located on the inner side and not accessible for AxV binding. 
Usually, AxV is combined with propidium iodide, making 
it possible to differentiate between apoptotic and necrotic 
cells, but since the emission wavelength of propidium iodide 
(620 nm) overlaps by the emission peak of hypericin (∼600 
nm), it is not used in our experiments.39
First of all, free hypericin was used as proof of principle 
for the phototoxicity of hypericin after light irradiation on 
Jurkat cells. Jurkat cells were treated with 0, 0.1, 0.2, and 
0.3 µg/mL hypericin and exposure time was 0, 5, 10, and 
15 minutes. Figure 7A exemplarily shows the results for 
the DiI staining 24 hours after exposure. Both the experi-
ments with DiI and AxV (data not shown) indicate that in 
the absence of light, hypericin does not display any toxic 
effects independent from the incubation time, confirming 
hypericin’s negligible dark toxicity.40 However, a concentra-
tion and exposure time-dependent increase in cytotoxicity can 
be clearly observed. With 15 minutes of light exposure, all 
hypericin concentrations cause complete cell death, whereas 
with shorter light exposure (5 and 10 minutes) not all cells are 
killed. In the samples with 5-minute exposure, a clear dose-
dependent cytotoxic effect of the hypericin can be observed. 
Interestingly, after incubation for 48 hours, proliferation of 
the surviving cells can be observed (Figure 7B) underlining 
the importance of initially high tumor cell killing rates in 
cancer therapy, especially for the fact that apoptotic cell 
death is immunologically silent and factors released from 
apoptotic cells might foster the compensatory proliferation 
of the surviving cells causing tumor cell repopulation.41
Based on these data for the following experiments, an 
intermediate hypericin concentration of 0.2 µg/mL was 
selected to investigate cytotoxic capacity of nanoparticle 
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loaded with hypericin. Free hypericin, SPIONCMD-Hyp (cor-
responding iron concentration: 30 µg/mL), and SPIONCMD 
in the presence of free hypericin were incubated with Jurkat 
cells and illuminated for the same times as aforementioned. 
Water and SPIONCMD served as controls. Figure 8A shows 
exemplary results for DiI staining 24 hours after exposure 
(corresponding AxV data are shown in Figure S1). In line 
with the experiment before, in the presence of hypericin and 
the absence of light cell remained viable, whereas hypericin 
in the presence of light induced cell death in an exposure 
time-dependent manner. Unloaded SPIONs (SPIONCMD) did 
not induce cell death at all.
Comparing the cytotoxic effect of free hypericin (Hyp 
and SPIONCMD + Hyp) and particle-bound hypericin 
(SPIONCMD-Hyp), free hypericin showed a stronger cytotoxic 
effect. In contrast, the presence of SPIONs in the free hyperi-
cin solution (SPIONCMD + Hyp) did not reduce the cytotoxic 
effect, indicating that binding of hypericin to the particles and 
not quenching of light is responsible for a lower cytotoxicity 
of SPION-bound hypericin. Again, prolonged incubation of 
cells after treatment showed proliferation of the surviving 
cells in the presence of free hypericin as well as in the pres-
ence of SPIONCMD-Hyp (Figure 8B).
In order to prove that the cytotoxic effects can be 
attributed to the ROS formation an assay with the hydro-
phobic and nonfluorescent DCFH-DA molecule is used. It 
is able to penetrate into cells, where intracellular esterases 
hydrolyze it to the nonfluorescent dichlorofluorescein 
(DCFH). In the presence of ROS, DCFH is oxidized to 
the  fluorescent dichlorofluorescein (FDCF), which can 
be detected by flow cytometry to quantify the amount of 
produced ROS.42 For the experiments, an intermediate 
hypericin concentration of 0.2 µg/mL was used. For pre-
vious phototoxicity investigations, cells were incubated 
in FCS containing culture medium, whereas for ROS 
determination using DCFH-DA cells were incubated in 
PBS. Preliminary tests showed that the change of the sus-
pension media increases the sensitivity of the cells toward 
the treatment, and therefore the irradiation time had to be 
reduced to 1 minute under these conditions. Figure 9 shows 
exemplary results in 5 minutes after light exposure. The 
fluorescence signal indicating the ROS generation was 
normalized to the control.
Without illumination, no increase in the FDCF fluores-
cence signal is detected and the cell viability is unchanged. 
However, after 1 minute light exposure, all samples with 
hypericin showed an increase in FDCF fluorescence indicat-
ing the generation of ROS. It is noteworthy that even the 
particles without hypericin produced a low amount of ROS, 
which might be due to the Fenton reaction that occurs by 
availability of Fe2+ of the particles in the presence of hydrogen 
peroxide.43 As a consequence, 5 minutes of incubation after 
light exposure, the FDCF intensity of SPIONCMD + hypericin is 
approximately the sum of the intensities of pure hypericin and 
SPIONCMD specimens. The intensity of SPIONCMD-Hyp is higher 
compared to SPIONCMD, but lower compared to the other 
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Figure 8 cell death of Jurkat cells determined by DiI staining 24 hours (A) and 48 hours (B) after treatment with sPIONcMD, sPIONcMD-hyp, sPIONcMD + hypericin not linked 
to the particles as well as hypericin alone at a hypericin concentration of 0.2 µg/ml.
Notes: DiI-positive cells were considered viable, DiI-negative cells were considered dying/dead. Without illumination all samples show no toxicity, whereas with increased 
exposure time (0, 5, 10, and 15 minutes) cell death can be observed. Figures show the mean values of triplicates with standard deviations. The statistical significance of 
comparisons with the untreated control was investigated using student’s t-test in excel (Microsoft corporation, redmond, Wa, Usa) (*P,0.05, **P,0.005, and ***P,0.0005).
Abbreviations: DiI, hexamethylindodicarbo-cyanine iodide; sPIONcMD, functionalized dextran-coated sPIONs; sPION, superparamagnetic iron oxide nanoparticle; 
sPIONcMD-hyp, hypericin linked to sPIONcMD.
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ones which is in agreement with the slower kinetics in the 
toxicological investigations. Furthermore, already 5 minutes 
after light exposure for 1 minute, cell death was induced as 
determined by characteristic morphological alterations of 
the cells, leading to the assumption that the predominant cell 
death mechanism is necrosis, because apoptosis is a more 
time-consuming process.44 With prolonged incubation after 
light exposition, the FDCF fluorescence signal of the samples 
with free hypericin decreases parallel with increasing cell 
death rates, whereas the SPION-bound hypericin produces a 
constant FDCF signal with lower cell death rates. This might 
be due to faster intracellular uptake and abreaction of free 
hypericin compared to nanoparticle bound hypericin.
Conclusion
In this project, dextran-coated and functionalized SPIONs, 
loaded with a sufficient amount of hypericin, were success-
fully synthesized for the first time. The particles were stable 
in water and PBS for several weeks, without any sign of 
agglomeration. The evaluation of the phototoxic behavior of 
the hypericin-bound particles was performed with the non-
adherent Jurkat cell line by investigating the viability of cells 
via DiI and AxV staining and flow cytometry. The experiment 
revealed that pure nanoparticles as well as hypericin were not 
toxic for the cells in the absence of light illumination, whereas 
drug-loaded particles induced cell death in a concentration and 
exposure time-dependent manner. Comparison of nanoparti-
cle-loaded hypericin to the controls treated with free hypericin 
indicated a weaker cytotoxic impact that can be explained by 
reducing effects of drug coupling to particles. This difference 
can still be compensated by adjusting the irradiation time. 
Furthermore, with a DCFH-DA assay, the origin of the cyto-
toxic behavior could be attributed to the generation of ROS. 
In conclusion, the combination of dextran-coated SPIONs 
loaded with hypericin represents a promising approach to be 
used in combined MDT and PDT for cancer therapy.
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Figure S1 cell death of Jurkat cells determined by axV staining 24 hours (A) and 48 hours (B) after treatment with sPIONcMD, sPIONcMD-hyp, and sPIONcMD + hypericin not 
linked to the particles as well as hypericin alone at a hypericin concentration of 0.2 µg/ml.
Notes: axV-negative cells were considered viable, axV-positive cells were considered dying/dead. Without illumination all samples show no toxicity, whereas with increased 
exposure time (0, 5, 10, and 15 minutes) cell death can be observed. Figure shows the mean values of triplicates with standard deviations. The statistical significance 
of comparisons with the untreated control was investigated using student’s t-test in excel (Microsoft corporation, redmond, Wa, Usa) (*P,0.05, **P,0.005, and 
***P,0.0005).
Abbreviations: axV, annexin V; sPIONcMD, functionalized dextran-coated sPIONs; sPION, superparamagnetic iron oxide nanoparticle; sPIONcMD-hyp, hypericin linked to 
sPIONcMD.
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